Compare YSXT & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | NSRX |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 37.1M |
| IPO Year | 2023 | 2024 |
| Metric | YSXT | NSRX |
|---|---|---|
| Price | $1.38 | $2.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 3.0K | ★ 14.0K |
| Earning Date | 07-10-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $1.98 |
| 52 Week High | $2.58 | $9.50 |
| Indicator | YSXT | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 29.72 |
| Support Level | $1.21 | $2.41 |
| Resistance Level | $1.31 | $3.61 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 39.18 | 4.49 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services, and Software Development and Information Technology Services. Key revenue is generated from the Auto Insurance Aftermarket Value-added Services segment, which includes four types of value-added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services, and vehicle maintenance and other value-added services.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.